A New Thienodiazepine, Brotizolam, for the Treatment of Insomnia

1982 ◽  
Vol 10 (2) ◽  
pp. 118-121 ◽  
Author(s):  
Jaime Sanchez-Martinez ◽  
Julia Landa-Palos
Keyword(s):  
Crossover Study ◽  
Total Sleep Time ◽  
Sleep Time ◽  
Primary Diagnosis ◽  
Chronic Insomnia ◽  
Double Blind ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

A double-blind crossover study was carried out in twenty hospitalized inpatients who, apart from their primary diagnosis, suffered from non-psychiatric chronic insomnia. The patients received 0·5 mg brotizolam or 30 mg flurazepam for a 2-week period. Both drugs improved the induction and continuity of sleep, and increased the total sleep time, although better results were observed with brotizolam in all the parameters studied.

Inhibition of Spontaneous Platelet Aggregation by Sulfinpyrazone

1979 ◽  
Vol 42 (02) ◽  
pp. 621-625 ◽  
Author(s):  
G G Nenci ◽  
G Agnelli ◽  
M Berrettini ◽  
P Parise ◽  
E Ballatori
Keyword(s):  
Platelet Aggregation ◽  
Crossover Study ◽  
Double Blind ◽  
Platelet Aggregability ◽  
Initiation Of Therapy ◽  
Spontaneous Platelet Aggregation ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

SummaryIn a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.

scholarly journals Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension

2021 ◽  
Author(s):  
Christos M. Polymeropoulos ◽  
Justin Brooks ◽  
Emily L. Czeisler ◽  
Michaela A. Fisher ◽  
Mary M. Gibson ◽  
...  
Keyword(s):  
Sleep Quality ◽  
Crossover Study ◽  
Total Sleep Time ◽  
Sleep Time ◽  
Open Label ◽  
Double Blind ◽  
Open Label Study ◽  
Label Study ◽  
Sleep Complaints ◽  
Open Label Extension

Abstract Purpose To assess the efficacy of tasimelteon to improve sleep in Smith–Magenis syndrome (SMS). Methods A 9-week, double-blind, randomized, two-period crossover study was conducted at four US clinical centers. Genetically confirmed patients with SMS, aged 3 to 39, with sleep complaints participated in the study. Patients were assigned to treatment with tasimelteon or placebo in a 4-week crossover study with a 1-week washout between treatments. Eligible patients participated in an open-label study and were followed for >3 months. Results Improvement of sleep quality (DDSQ50) and total sleep time (DDTST50) on the worst 50% of nights were primary endpoints. Secondary measures included actigraphy and behavioral parameters. Over three years, 52 patients were screened, and 25 patients completed the randomized portion of the study. DDSQ50 significantly improved over placebo (0.4, p = 0.0139), and DDTST50 also improved (18.5 minutes, p = 0.0556). Average sleep quality (0.3, p = 0.0155) and actigraphy-based total sleep time (21.1 minutes, p = 0.0134) improved significantly, consistent with the primary outcomes. Patients treated for ≥90 days in the open-label study showed persistent efficacy. Adverse events were similar between placebo and tasimelteon. Conclusion Tasimelteon safely and effectively improved sleep in SMS.

scholarly journals Erratum: Bosch-Sierra, N., et al. Effect of Fibre-Enriched Orange Juice on Postprandial Glycaemic Response and Satiety in Healthy Individuals: An Acute, Randomised, Placebo-Controlled, Double-Blind, Crossover Study. Nutrients 2019, 11, 3014

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 696
Author(s):  
Neus Bosch-Sierra ◽  
Roger Marqués-Cardete ◽  
Aránzazu Gurrea-Martínez ◽  
Carmen Grau-Del Valle ◽  
Clara Talens ◽  
...  
Keyword(s):  
Crossover Study ◽  
Orange Juice ◽  
Healthy Individuals ◽  
Glycaemic Response ◽  
Double Blind ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The authors have requested that the following changes be made to their paper [...]

Sign in / Sign up

Export Citation Format

Share Document